Hologic (HOLX) investor relations material

Executive summary

• Entered into a definitive agreement to be acquired by Blackstone and TPG for up to $79.00 per share, including a contingent value right tied to Breast Health revenue metrics; transaction expected to close in H1 2026, pending approvals.

• Revenue reached $1,047.8 million, up 2.5% year-over-year, with organic revenue excluding COVID-19 and certain businesses up 2.9%.

• GAAP diluted EPS was $0.79, down 9.2%, while non-GAAP diluted EPS rose 1.0% to $1.04.

• Completed the acquisition of Gynesonics for $340.7 million, expanding the GYN Surgical segment.

• Resolved BioZorb litigation with no financial liability due to insurance coverage.

Financial highlights

• Revenue for the quarter ended December 27, 2025 was $1,047.8 million, up 2.5% year-over-year.

• Net income was $179.1 million, down from $201.0 million in the prior year quarter.

• Diluted EPS was $0.79, compared to $0.87 in the prior year quarter.

• Operating cash flow was $229.9 million, up from $189.3 million year-over-year.

• Cash and cash equivalents at quarter end were $2,168.0 million.

Outlook and guidance

• Management expects the merger to close in the first half of 2026, subject to customary conditions.

• No annual or quarterly financial guidance for fiscal 2026 is being provided due to the pending acquisition.